No Data
No Data
Press Release: Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
Quoin Pharmaceuticals Shares Are Trading Higher After the Company Announced It Received FDA Clearance to Initiate a New QRX003 Netherton Syndrome Clinical Study.
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Quoin Pharmaceuticals Announces Positive Interim Data From Two Ongoing Netherton Syndrome Clinical Studies
Quoin Pharmaceuticals to Sell Up to 19.2M Ordinary Shares Represented by American Depositary Shares, Together With Series F and Series G Warrants
Unlock the Full List